HUP0302647A2 - Eljárás 5-(4-fluor-fenil)-1-[2-((2R,4R)-4-hidroxi-6-oxo-tetrahidropirán-2-il)-etil]-2-izopropil-4-fenil-1H-pirrol-3-karbonsav-fenil-amid és közbenső termékei előállítására - Google Patents

Eljárás 5-(4-fluor-fenil)-1-[2-((2R,4R)-4-hidroxi-6-oxo-tetrahidropirán-2-il)-etil]-2-izopropil-4-fenil-1H-pirrol-3-karbonsav-fenil-amid és közbenső termékei előállítására

Info

Publication number
HUP0302647A2
HUP0302647A2 HU0302647A HUP0302647A HUP0302647A2 HU P0302647 A2 HUP0302647 A2 HU P0302647A2 HU 0302647 A HU0302647 A HU 0302647A HU P0302647 A HUP0302647 A HU P0302647A HU P0302647 A2 HUP0302647 A2 HU P0302647A2
Authority
HU
Hungary
Prior art keywords
fluorophenyl
pyrrole
isopropyl
hydroxy
phenyl
Prior art date
Application number
HU0302647A
Other languages
English (en)
Inventor
Donald Eugene Butler
Randall Lee Dejong
Jade Douglas Nelson
Michael Gerard Pamment
Timothy Lee Stuk
Original Assignee
Warner Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Company Llc filed Critical Warner Lambert Company Llc
Publication of HUP0302647A2 publication Critical patent/HUP0302647A2/hu
Publication of HUP0302647A3 publication Critical patent/HUP0302647A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)

Abstract

A találmány tárgyát eljárás képezi 5-(4-fluor-fenil)-1-[2-((2R,4R)-4-hidroxi-6-oxo-tetrahidropirán-2-il)-etil]-2-izopropil-4-fenil-1H-pirrol-3-karbonsav-fenil-amid (13) előállítására; a találmány tárgyátképezi ezen kívül a (8) általános képletű és a (11b) általános képletűvegyület előállítására szolgáló eljárás is. A találmány tárgyátképezik a (6), (8) és (10) általános képletű, a (12) képletű, valaminta (18) és (18a) általános képletű közbenső termékek is. A találmánytárgyát képező 5-(4-fluor-fenil)-1-[2-((2R,4R)-4-hidroxi-6-oxotetrahidropirán-2-il)-etil]-2-izopropil-1-4-fenil-1H-pirrol-3-karbons v-fenil-amid (13) értékes közbenső termék és az atorvasztatik-kalcium előállításához alkalmazható. A találmány szerinti eljárásnyolc lépésben vagy ennél kevesebb lépésben végezhető. Az általánosképletekben a szubsztituensek jelentése igen sokféle, így például Rjelentése alkil-, aril-, aril-alkil- vagy heteroarilcsoport; R1jelentése ahol R2 vagy R3 jelentése egymástól függetlenül példáulcikloalkil-, aril-alkil- vagy arilcsoport vagy R2 és R3 együttesjelentése -(CH2)4-, -(CH(R4)-CH2)3-, -(CH(R4)-(CH2)2-CH(R4))-, -CH2-CH2-A-CH2-CH2-, -(CH(R4)-CH2-A-CH2-CH(R4)-, ahol R4 jelentése 1-4szénatomos alkilcsoport, A jelentése O, S vagy N, M jelentése példáulnátrium-, kálium-, magnézium. Ó
HU0302647A 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide and their intermediates HUP0302647A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26050501P 2001-01-09 2001-01-09
PCT/IB2001/002729 WO2002055519A2 (en) 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide

Publications (2)

Publication Number Publication Date
HUP0302647A2 true HUP0302647A2 (hu) 2003-11-28
HUP0302647A3 HUP0302647A3 (en) 2009-03-30

Family

ID=22989433

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302647A HUP0302647A3 (en) 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide and their intermediates

Country Status (25)

Country Link
US (7) US6476235B2 (hu)
EP (1) EP1353917B1 (hu)
JP (2) JP4190285B2 (hu)
KR (3) KR100833911B1 (hu)
CN (4) CN1222521C (hu)
AR (1) AR035680A1 (hu)
AT (1) ATE358126T1 (hu)
BR (1) BR0116739A (hu)
CA (1) CA2432064C (hu)
CY (1) CY1106590T1 (hu)
CZ (1) CZ20031893A3 (hu)
DE (1) DE60127583T2 (hu)
DK (1) DK1353917T3 (hu)
ES (1) ES2282200T3 (hu)
HK (2) HK1060572A1 (hu)
HU (1) HUP0302647A3 (hu)
IL (4) IL156461A0 (hu)
MX (1) MXPA03005284A (hu)
PL (1) PL365283A1 (hu)
PT (1) PT1353917E (hu)
RU (1) RU2244714C1 (hu)
TW (1) TWI293073B (hu)
WO (1) WO2002055519A2 (hu)
YU (1) YU49003A (hu)
ZA (1) ZA200304684B (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
HUP0401014A2 (hu) * 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100765555B1 (ko) * 2002-08-06 2007-10-09 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2ｒ,4ｒ)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1ｈ-피롤-3-카르복실산 페닐아미드의 제조 방법
CA2494269A1 (en) 2002-08-06 2004-02-19 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
WO2004046105A2 (en) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
WO2004089894A1 (en) 2003-04-14 2004-10-21 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
JP5009613B2 (ja) * 2003-06-13 2012-08-22 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不斉合成における使用のためのキラル配位子
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
CN102030645A (zh) 2003-10-24 2011-04-27 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CZ299175B6 (cs) * 2004-06-17 2008-05-07 Zentiva, A. S Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
BRPI0513677B8 (pt) * 2004-07-30 2021-05-25 Exelixis Inc derivados de pirrol como agentes farmacêuticos
BRPI0519996A2 (pt) 2004-10-28 2009-04-07 Warner Lambert Co processo para formar atorvastatina amorfa
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
CA2601111A1 (en) * 2005-03-14 2006-09-21 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1705175A1 (en) * 2005-03-24 2006-09-27 ratiopharm GmbH Process for preparing C5 products and their use for Atorvastatin synthesis
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
WO2007131528A1 (en) * 2006-05-15 2007-11-22 Ratiopharm Gmbh Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives
KR101069698B1 (ko) * 2008-08-28 2011-10-04 한국화학연구원 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
KR100986755B1 (ko) * 2009-12-29 2010-10-08 김우진 노즐 회전장치 및 이를 갖는 분수
CN101892276B (zh) * 2010-06-12 2012-11-21 郝志艳 一种阿托伐他汀钙化合物及其新方法
US20130178636A1 (en) 2010-09-16 2013-07-11 Dsm Sinochem Pharmaceuticals Netherlands B.V. Esters of hexanoic acids as intermediates for the preparation of atorvastatin
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
JP6970105B2 (ja) * 2016-02-11 2021-11-24 スティヒティング カソリーケ ユニベルシタイトStichting Katholieke Universiteit 心血管疾患の治療のための新規クラスの化合物
US11657391B1 (en) 2019-05-24 2023-05-23 Hiro Systems Pbc System and method for invoking smart contracts
US10699269B1 (en) * 2019-05-24 2020-06-30 Blockstack Pbc System and method for smart contract publishing
US11513815B1 (en) 2019-05-24 2022-11-29 Hiro Systems Pbc Defining data storage within smart contracts
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CZ294108B6 (cs) 1995-07-17 2004-10-13 Warner@Lambertácompany Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové
US6297274B1 (en) * 1996-04-10 2001-10-02 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IL127058A (en) 1996-07-29 2001-07-24 Warner Lambert Co Process for the synthesis of protected esters of acid (S) - 4,3 dehydroxybutyric
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
ES2282200T3 (es) 2007-10-16
KR100677008B1 (ko) 2007-02-01
CN1907984A (zh) 2007-02-07
MXPA03005284A (es) 2003-09-25
US7371855B2 (en) 2008-05-13
KR100833911B1 (ko) 2008-06-03
IL189359A0 (en) 2008-06-05
TWI293073B (en) 2008-02-01
JP4190285B2 (ja) 2008-12-03
KR20060114395A (ko) 2006-11-06
HK1084114A1 (en) 2006-07-21
ZA200304684B (en) 2004-06-28
US7399773B2 (en) 2008-07-15
IL156461A0 (en) 2004-01-04
HK1060572A1 (en) 2004-08-13
CZ20031893A3 (cs) 2004-03-17
US20070032664A1 (en) 2007-02-08
US7361771B2 (en) 2008-04-22
WO2002055519A3 (en) 2002-09-19
AU2002222430B2 (en) 2007-05-17
US20070032663A1 (en) 2007-02-08
US6476235B2 (en) 2002-11-05
WO2002055519A2 (en) 2002-07-18
DK1353917T3 (da) 2007-06-18
CN1696129A (zh) 2005-11-16
US7183408B2 (en) 2007-02-27
EP1353917B1 (en) 2007-03-28
KR100582326B1 (ko) 2006-05-22
RU2244714C1 (ru) 2005-01-20
CN1222521C (zh) 2005-10-12
CN100351252C (zh) 2007-11-28
US6545153B1 (en) 2003-04-08
US20070032662A1 (en) 2007-02-08
AR035680A1 (es) 2004-06-23
ATE358126T1 (de) 2007-04-15
CN1489587A (zh) 2004-04-14
PT1353917E (pt) 2007-05-31
EP1353917A2 (en) 2003-10-22
YU49003A (sh) 2006-05-25
JP2008100989A (ja) 2008-05-01
US20020133026A1 (en) 2002-09-19
DE60127583D1 (de) 2007-05-10
BR0116739A (pt) 2003-09-30
HUP0302647A3 (en) 2009-03-30
CA2432064C (en) 2007-09-11
PL365283A1 (en) 2004-12-27
US20030195353A1 (en) 2003-10-16
CY1106590T1 (el) 2012-01-25
CN101024626A (zh) 2007-08-29
KR20030065594A (ko) 2003-08-06
US20050239869A1 (en) 2005-10-27
IL189358A0 (en) 2008-06-05
CA2432064A1 (en) 2002-07-18
US6933393B2 (en) 2005-08-23
IL189357A0 (en) 2008-06-05
KR20060015698A (ko) 2006-02-17
DE60127583T2 (de) 2007-12-06
JP2004520351A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
HUP0302647A2 (hu) Eljárás 5-(4-fluor-fenil)-1-[2-((2R,4R)-4-hidroxi-6-oxo-tetrahidropirán-2-il)-etil]-2-izopropil-4-fenil-1H-pirrol-3-karbonsav-fenil-amid és közbenső termékei előállítására
HUP0402107A2 (hu) N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200001135A1 (ru) Способ получения изоксазолин-3-ил-ацилбензолов
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
US6025516A (en) Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
EA200400111A1 (ru) 7-аминотриазолопиримидины, способ и промежуточные продукты для их получения, содержащие их средства, а также их применение для борьбы с фитопатогенными грибами
NO20062656L (no) Fremgangsmate for fremstilling av statiner
HUT41770A (en) Process for producing indol derivatives containing heterocyclic substituents and pharmaceutical compositions containing them
IL175940A0 (en) Prostaglandin synthesis
HUP9900318A2 (hu) Eljárás 4-aril-piperidin-származékok előállítására
MXPA03012045A (es) Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
NO20071253L (no) Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer.
HUP0401600A2 (hu) Eljárás 14-hidroximorfin-származékok előállítására
Panduwawala et al. Chemoselectivity and stereoselectivity of cyclisation pathways leading to bicyclic tetramates controlled by ring-chain tautomerisation in thiazolidines
HUP0202006A2 (hu) Eljárás 2-amino-4-(4-fluorfenil)-6-alkil-pirimidin-5-karboxilát-származékok előállítására
WO2004078100A3 (en) A poymerizable phosphoric acid ester derivative and a dental composition employing it.
SI1102765T1 (en) PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
DE69634345D1 (de) Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen
KR940014808A (ko) 헤테로비사이클릭 알콜 에난티오머의 입체선별적 제조를 위한 효소적 방법
ATE208381T1 (de) Verfahren zur herstellung von taxol und seiner derivate
NZ335105A (en) Process for alkylating hindered sulfonamides
HUP0300154A2 (en) Method for the production of spirocyclic tetronic acid derivatives
HUP0203365A2 (hu) Rinovírus proteáz inhibitorok szintetikus előállítási eljárása és az eljárás köztitermékei
EA199900528A1 (ru) Новые производные эритромицина, способ их получения и применения в качетве медикаментов
HUP0204444A2 (en) Phenyl- and pyridyl-tetrahydro-pyridines, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished